https://www.selleckchem.com/pr....oducts/telratolimod.
001). On multivariate analysis, RASIs administration was identified as an independent prognostic factor for TTR [hazard ratio (HR) =0.52, 95% confidence interval (CI), 0.38-0.70, P less then 0.001] and OS (HR =0.50, 95% CI, 0.34-0.74, P less then 0.001). Patients in the RASI group had lower rates of extrahepatic metastases than patients in the non-RASI group (2.8% vs. 7.8%, P less then 0.042). Conclusions Targeting the RAS was associated with a reduced risk of recurrence, decreased rate of extrahepatic metastases and prolonged surv
Curtir
Comentario
Compartilhar
